Abiopharma

🔍 Schambye Hans T. (Executive)

Company: Galecto, Inc. (GLTO)

Report Date: 2026-01-02

Detailed Transactions and Holdings:

• Acquired 1,360 shares of Common Stock (Direct)
  Date: 2026-01-02 | Code: M | equity_swap_involved: false | shares_owned_after: 5,382.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 700 shares of Common Stock at $21.38 per share (Direct)
  Date: 2026-01-02 | Code: S | equity_swap_involved: false | shares_owned_after: 4,682.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 1,360 shares of Restricted Stock Units (Derivative)
  Date: 2026-01-02 | Code: M | equity_swap_involved: false | shares_owned_after: 2,640.00 | transaction_form_type: 4 | Footnotes: F1, F3, F3

Footnotes:

• F1: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date.
• F2: Shares sold to cover tax obligations in connection with the vesting of the RSUs listed in Table II. This sale is mandated by the Issuer's election under its 2020 Equity Incentive Plan and does not represent a discretionary trade by the Reporting Person.
• F3: This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date.